Drug screening model meets cancer organoid technology
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
Progress and potential in organoid research
Rossi, G., Manfrin, A., & Lutolf, M. P. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0051-9 · Cited by 1,182 · cited 1×
“rapid development of cancer organoid technology, tumor organoids will be first expected to predict the effectiveness and accuracy of drug responses in vitro [106].”
BackgroundJacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092
Long‐term expanding human airway organoids for disease modeling
Sachs, N., Papaspyropoulos, A., Zomer‐van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., Weeber, F., Huelsz‐Prince, G., Iakobachvili, N., Amatngalim, G. D., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100300 · Cited by 1,082
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999 · cited 1×
“The traditional tumor organoids activity delivered the results of drug screening, which had been utilized bymany researchers [40,41].”
BackgroundCancer modeling meets human organoid technology
Tuveson, D., & Clevers, H. (2019) · Science · doi:10.1126/science.aaw6985 · Cited by 935 · cited 1×
“In the era of precision oncology, scientists and oncologists were committed to finding drug screening models that would be more effective, realistic, time-saving and labor-saving to study the response of tumor patients to drugs [2,3].”
BackgroundModelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906 · cited 1×
“In a lung cancer organoid chip, lung cancer cells invaded vascular channels and migrated to the distant liver, bone, or brain chip; metastatic diffusion could be detected, and the growth of metastatic lesions could be identified and studied [50,51].”
BackgroundTumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
STUDIES ON THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES
Scherer, W. F., Syverton, J. T., & Gey, G. O. (1953) · Journal of Experimental Medicine · doi:10.1084/jem.97.5.695 · Cited by 856
Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K., Ohta, Y., Toshimitsu, K., Nakazato, Y., Kawasaki, K., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.003 · Cited by 852
Park, S. E., Georgescu, A., & Huh, D. (2019) · Science · doi:10.1126/science.aaw7894 · Cited by 847
Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids
Hu, H., Gehart, H., Artegiani, B., LÖpez-Iglesias, C., Dekkers, F., Basak, O., van Es, J., Chuva de Sousa Lopes, S. M., Begthel, H., Korving, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.013 · Cited by 837
Broutier, L., Andersson-Rolf, A., Hindley, C. J., Boj, S. F., Clevers, H., Koo, B.-K., & Huch, M. (2016) · Nature Protocols · doi:10.1038/nprot.2016.097 · Cited by 834
Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay2574 · Cited by 813
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.10.010 · Cited by 755
Self-citationYan, H. H. N., Siu, H. C., Law, S., Ho, S. L., Yue, S. S. K., Tsui, W. Y., Chan, D., Chan, A. S., Ma, S., Lam, K. O., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.09.016 · Cited by 724
Phase II and phase III failures: 2013–2015
Harrison, R. K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.184 · Cited by 636 · cited 1×
“found that most drug candidate attrition in Phase II and Phase III for the period 2013–2015 was due to the lack of effectiveness (52%) and safety (24%) [1].”
BackgroundA rectal cancer organoid platform to study individual responses to chemoradiation
Ganesh, K., Wu, C., O’Rourke, K. P., Szeglin, B. C., Zheng, Y., Sauvé, C.-E. G., Adileh, M., Wasserman, I., Marco, M. R., Kim, A. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0584-2 · Cited by 569
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer
Renz, B. W., Takahashi, R., Tanaka, T., Macchini, M., Hayakawa, Y., Dantes, Z., Maurer, H. C., Chen, X., Jiang, Z., Westphalen, C. B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.007 · Cited by 543
Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
Nuciforo, S., Fofana, I., Matter, M. S., Blumer, T., Calabrese, D., Boldanova, T., Piscuoglio, S., Wieland, S., Ringnalda, F., Schwank, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.001 · Cited by 473
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452
Tumor organoid–T-cell coculture systems
Cattaneo, C. M., Dijkstra, K. K., Fanchi, L. F., Kelderman, S., Kaing, S., van Rooij, N., van den Brink, S., Schumacher, T. N., & Voest, E. E. (2020) · Nature Protocols · doi:10.1038/s41596-019-0232-9 · Cited by 410
Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy
Driehuis, E., Kolders, S., Spelier, S., Lõhmussaar, K., Willems, S. M., Devriese, L. A., de Bree, R., de Ruiter, E. J., Korving, J., Begthel, H., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1522 · Cited by 408
Organoids in immunological research
Bar-Ephraim, Y. E., Kretzschmar, K., & Clevers, H. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0248-y · Cited by 361 · cited 1×
“co-cultured tumor organoids and immune cells to study the interaction between tumor cells and immune cells [100].”
BackgroundA Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
Kondo, J., Endo, H., Okuyama, H., Ishikawa, O., Iishi, H., Tsujii, M., Ohue, M., & Inoue, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015938108 · Cited by 322
Shirure, V. S., Bi, Y., Curtis, M. B., Lezia, A., Goedegebuure, M. M., Goedegebuure, S. P., Aft, R., Fields, R. C., & George, S. C. (2018) · Lab on a Chip · doi:10.1039/c8lc00596f · Cited by 316
Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Shi, R., Radulovich, N., Ng, C., Liu, N., Notsuda, H., Cabanero, M., Martins-Filho, S. N., Raghavan, V., Li, Q., Mer, A. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1376 · Cited by 316
Li, X., Francies, H. E., Secrier, M., Perner, J., Miremadi, A., Galeano-Dalmau, N., Barendt, W. J., Letchford, L., Leyden, G. M., Goffin, E. K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05190-9 · Cited by 316
Mills, R. J., Parker, B. L., Quaife-Ryan, G. A., Voges, H. K., Needham, E. J., Bornot, A., Ding, M., Andersson, H., Polla, M., Elliott, D. A., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.03.009 · Cited by 312
Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery
Sharma, A., Sances, S., Workman, M. J., & Svendsen, C. N. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.02.011 · Cited by 296
Khoo, B. L., Grenci, G., Lim, Y. B., Lee, S. C., Han, J., & Lim, C. T. (2018) · Nature Protocols · doi:10.1038/nprot.2017.125 · Cited by 172
Liu, J. F., Palakurthi, S., Zeng, Q., Zhou, S., Ivanova, E., Huang, W., Zervantonakis, I. K., Selfors, L. M., Shen, Y., Pritchard, C. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1237 · Cited by 127
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115
Usui, T., Sakurai, M., Umata, K., Elbadawy, M., Ohama, T., Yamawaki, H., Hazama, S., Takenouchi, H., Nakajima, M., Tsunedomi, R., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041098 · Cited by 96
Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K.-M., Formisano, L., Guo, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.013 · Cited by 49
Cited by
Allgayer, H., Mahapatra, S., Mishra, B., Swain, B., Saha, S., Khanra, S., Kumari, K., Panda, V. K., Malhotra, D., Patil, N. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02338-2 · Cited by 127
Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems
Silva-Pedrosa, R., Salgado, A. J., & Ferreira, P. E. (2023) · Cells · doi:10.3390/cells12060930 · Cited by 84
Boghaert, E. R., Cox, M. C., & Vaidya, K. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3236 · Cited by 17
Metadata
- Authors
- Liu, C., Qin, T., Huang, Y., Li, Y., Chen, G., & Sun, C.
- Venue
- Translational Oncology
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 13
- Issue
- 11
- Pages
- 100840
- ISSN
- 1936-5233 (ISSN-L)
- OpenAlex
- W3069202567
- Cited by
- 71
- References
- 44
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.